First in Class
Therapeutics for Cancer

By coming together,
we stand apart.

Cambium Oncology is a team of scientists, drug development experts, cancer physicians, and business leaders united in a shared vision of treating cancer with a novel immunotherapeutic that targets the VIP signaling pathway. Emory investigators discovered that small molecule antagonists to the VIP receptor on T cells could augment T cell-mediated immune responses to cancer, viral infections, and vaccines. Cambium scientists developed and patented more potent molecules with longer half-lives that induce potent anti-cancer immune responses to leukemia and pancreatic cancer. Cambium Oncology is poised to transform the immuno-oncology field, with a first-in-class therapeutic against a novel immune check-point pathway.

News &
Publications

See all